Antinicotine alcohol product

The invention relates to medicine, specifically to medicines from plants

The invention relates to medicine, specifically to therapeutic methods for treating tobacco

The invention relates to medicine, specifically to medicines on the basis of herbal remedies designed to treat tobacco

The invention relates to driven the breath inhaler, having, in General, a tubular shape and having two ends, with one end forms the air intake, and the other end of the vent hole, and the inhaler contains a powder of a pharmaceutical product containing particles of respirable size

The invention relates to the field of medical technology

Inhaler has catalytic burner, fuel balloon 6 containing hydrogen, said balloon being connected to burner, reservoir 15 for inhaling additives such as aromatic substances and/or functioning substances, at least one inlet 2 for oxygen-containing gaseous mixture, preferably for air, and at least one outlet 3 for inhaling mixture containing aromatic substances and/or functioning substances.

Method involves administering Surfactant BL in discrete small doses in addition to traditional therapy. Dose of 75 mg is dissolved in 2.5 ml of physiologic saline and introduced by means of bronchoalveolar nebulizer within 2 h three times at a dose of 25 mg.

Method involves introducing ozonized physiologic saline once a day during 30 min in addition to traditionally applied drugs. The ozonized solution has ozone in concentration of 100-150 mcg/l in the amount of 100-150 ml when treating children younger than 3 years. Children being elder then 3 years, ozone concentration is 200-250 mcg/l, its amount is 200-250 ml. The total therapy course is 5 days long. The traditionally applied drugs are not to be used within 30 min before and after ozonized physiologic saline application.

Invention refers to medicine and namely to devices for inhalation of various substances, preferably medicinal substances, to the human organism through airways. Inhalation cigarette consists of a cylindrical tube inside which there located is burnable filler, porous material with inhalation device and a filtering material. Cylindrical tube is made from heat-insulating material, covered on the outside with a thin antioxidant layer and consists of the rim made from cigarette paper on the side of the filtering material. Burnable filler is made in the form of chips which are covered on the outside with thin smoke agent layer. Polyolefine or granulated heat-resistant coal has been used as porous material. Acetate cellulose has been used as filter material. As burnable filler material, there has been used one of the materials of the group including calcium, aluminium, zinc, magnesium or their alloys.

Invention relates to the process of biologically active and/or aromatic substances volatilisation for purposes of inhalable aerosol extraction in the course of the smoker imitating the act of a regular cigarette smoking. Gaseous products of combustion of flammable gas burnt (preferably - under oxygen excess conditions) partly or wholly, are supplied (in case of necessity - mixed with ambient air) through the biologically active and/or aromatic substances depot. The desirable temperature is selected by the gaseous combustion products content, in case of necessity - by the components ratio of the mixture of such gaseous combustion products with ambient air. The device for the method implementation includes a mouthpiece containing the biologically active and/or aromatic substances depot and a heating core. The core contains the body shell, a filling valve for filling a tiny gas reservoir with flammable gas, a regulator valve for controlled discharge of gas from the gas reservoir onto the burner and the substance converter for air heating with thermal energy generated by the burner. The mouthpiece is connected so that to enable its disconnection from the cigarette- or cigar-shaped heating rod for output of inhalable aerosol. Control of the regulator valve is performed by means of depression suction provided for on the mouthpiece and/or by means of air flow.

Invention refers to medicine, particularly medical devices applicable for drug introduction in the form of inhalation, as well as a therapeutic simulator. The inhaler represents a smoking pipe wherein a pivoted lid tightly closes a liquid container. An entry of a portion of an outlet is truncated at the angle of 45-60° and arranged under the lid on a container axis. A disk is supplied on an annular groove on a lower portion of the container and gapped from the bottom. A cylinder outlet hole of the outlet is formed above the lid on an outlet stem with the outlet hole of the outlet and the outlet have supplementary tightly closed caps; and the gap of the disk and the outlet there is a smoothing chamber.

Imitative smoking device (1,51) contains an imitative cigarette having an essentially cylindrical cigarette-like shape and a charging unit (2, 50) having an essentially rectangular body shaped like a cigarette packet. The filling device (2, 50) contains charging gas (32, 59) for the imitative cigarette and a means for elective retention of the imitative cigarette. The imitative cigarette may be completely retained inside the body (3, 52). The cigarette may be retained at a place other than the charging place. A dose counter may be envisaged to give visual indication of doses in the charging device.

Invention refers to medicine, namely to addiction medicine, psychotherapy, and pulmonology. What is used is an electronic cigarette containing a cartridge with a drug and trace amount of mint extract, and a blue light emitter. A monochromatic blue light emitter is actuated with air inhalation through the cigarette. The method enables reducing a dose of the drug administered by the blue light exposure with enhancing the therapeutic efficacy, reducing the requirement of nicotine by actuating the mechanism of nicotinic acid and nicotinamide self-reproduction from the nutrients, having the immune stimulating effect ensured by using blue light, increasing the patient's compliance by simplicity and familiarity of the device in use, eliminating the development of the stress response to smoking drop.

Invention relates to an aroma inhalation pipe including a hollow cylindrical pipe body (10), a tobacco cartridge (12) placed as a cartridge for aroma generation in the pipe body (10), a tip (30) connected to the tobacco cartridge (12) and projecting out of the pipe body (10) and a connective device (40) connecting the pipe body (10) and the tip (30) to each other; the connective device (40) has a connection position, wherein the tip (30) is clamped to the pipe body (10) with preset pushing force to elastically connect these two elements, and a free position that is assumed after the tip (30) being in the connection position, is pushed into the pipe body (10), turned and disengaged from connection to the pipe body (10).

Invention refers to medical equipment. Inhaler comprises a body with a container, as well as with an output end and an opposite end. A composition path for composition flow extends from the container along the flow path and from a composition output at the output end of the body. A flexible diaphragm in the body determines an air flow path from the air output at the output end of the body with the diaphragm extending past the air output to the opposite end separating the air flow on one side of the diaphragm from the rest of the body on the opposite side of the diaphragm. A valve element is movable together with the diaphragm.

Invention proposes applying N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazol-3-carboxamide or its salt for manufacturing a medicinal agent used for treatment of nicotine dependence and/or symptoms of nicotine withdrawal syndrome and a method for help in ceasing using tobacco. The claimed compound is known as antagonist of central cannabinoid receptors and agent used for treatment of disorders associated with using psychoactive substances. Indicated compounds are effective with respect to complete or partial tobacco abstinence with elimination of attenuation of nicotine withdrawal syndrome and patients show reduced weight loss or its absence.

Invention proposes applying the following agonists of gamma-aminobutyric acid receptors of B-type: β-(4-chlorophenyl)-GABA (Baclofen), 3-aminopropyl(methyl)-phosphinic acid, 3-aminopropylphosphinic acid, Y-amino-β-4-(4-chlorophenyl)-nitropropane or their salts, esters, ethers, complexes and their corresponding isomers used in treatment of nicotine dependence. Invention provides the selective suppression of smoking addiction and effect on behavior indices causing the abuse relapse and with absence of symptoms typical in nicotine dependence.

Method involves delivering nicotine to patient organism and administering medicament by smearing internal surface of superior and inferior nasal passage part. Treatment is carried out with cigarette consumption being retained. Smell receptor canal blocker like rapid sodium canal blocker lidocaine is used as the medicament. Its aerosol is introduced immediately before smoking action as single jet in each nasal passage. Medicament introduction is localized with epithelial smell receptor cells arrangement.

Invention relates to a sustained-release medicinal formulation designated for reducing abuse to nicotine. The medicinal formulation comprises 5,8,14-triazatetracyclo[10.3.1.0^2,11.0^4,9]hexadeca-2(11),3,5,7,9-pentaene or its pharmaceutically acceptable salt that is administrated in patient at the rate less 6 mg/h that corresponds to at least 0.1 mg of indicated compound for 24 h. Also, invention relates to the sustained-release medicinal formulation comprising low dose of indicated medicinal substance. Method for using involves oral administration of the sustained-release medicinal formulation at the first stage for period from about 1 day to about 30 days followed by administration the sustained-release medicinal formulation at the second stage. Invention provides reducing abuse for nicotine and simultaneous decreasing appearance of nausea frequency as adverse effect.

Invention represents a pharmaceutical tablet comprising a core and bound envelope wherein (a) core comprises solid particles of water-soluble dye dispersed in matrix, and (b) envelope comprises hellanic gum. Due to the presence of water-soluble dye in the tablet core it shows spotted shape that provides easy recognition of the tablet. The tablet is useful for peroral and intraoral administration.